Nkarta (NKTX) Preferred Stock Liabilities (2019 - 2020)
Nkarta's (NKTX) quarterly Preferred Stock Liabilities came in at $59.8 million in Q2 2020, up 361.18% year-on-year from $13.0 million in Q3 2019, and little changed quarter-over-quarter from $59.8 million in Q1 2020.
Nkarta (NKTX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Nkarta's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $59.8 million for Q2 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 361.18% year-over-year to $59.8 million in Q2 2020; TTM through Jun 2020 was $59.8 million, a 361.18% increase from a year earlier, with the FY2019 full-year figure at $59.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $59.8 million in Q2 2020 per NKTX's latest filing, from $59.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $59.8 million in Q4 2019 and bottomed at $13.0 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 59.82 Mn |
| Mar 31, 2020 | 59.82 Mn |
| Dec 31, 2019 | 59.82 Mn |
| Sep 30, 2019 | 54.36 Mn |
| Jun 30, 2019 | 12.97 Mn |